NEW YORK (GenomeWeb) – Molecular diagnostics firm T2 Biosystems has filed for an initial public offering, seeking to raise as much as $69 million in proceeds.

The Lexington, Mass.-based firm plans to list its shares on the Nasdaq Global Market under ticker symbol "TTOO," it said in its Form S-1 filed with the US Securities and Exchange Commission on Tuesday. The underwriters on the offering are Goldman Sachs, Morgan Stanley, Leerink Partners, and Janney Montgomery Scott.

T2 Bio has not priced its shares or said how many shares it plans to offer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.

Oct
23
Sponsored by
PerkinElmer

This webinar will address a range of methods for optimizing small RNA library preparation.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Nov
29
Sponsored by
Schott

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.